Trial · NCT02383433
Adverse events52
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 52
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | Gastrointestinal disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Alkaline phosphatase increased | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 2 |
| other | alkaline phosphatase, increased gr1 | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | ALT increased | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 8 |
| other | ALT increased, gr1 | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Aspartate Aminotransferase Increased | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | AST increased | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Colitis | Gastrointestinal disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | decreased platelets | Investigations | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Dehydration | Metabolism and nutrition disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | depression | Psychiatric disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Dizziness | Nervous system disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Headache | Nervous system disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 2 |
| other | Hepatic Vein Thrombosis | Vascular disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 2 |
| other | Hyperglycemia, gr1 | Metabolism and nutrition disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | hypertension | Vascular disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 6 |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 1 |
| other | Hypokalemia | Metabolism and nutrition disorders | Treatment (Regorafenib, Gemcitabine Hydrochloride) | 1 | 2 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02383433/events